Zinc finger CCHC domain-containing protein 9 (ZCCHC9)

Zinc finger CCHC domain-containing protein 9 (ZCCHC9) is a CCHC-type zinc finger protein that predominantly exhibits RNA-binding activity. It is classified within the zinc finger protein and protein phosphatase 1 regulatory subunit families[2][4]. Under physiological conditions, ZCCHC9 is localized mainly in the nucleus of normal tissues, such as bronchial epithelium, but in non-small cell lung cancer (NSCLC), it shifts to the cytoplasm, where its overexpression supports increased cell proliferation and invasion[2]. Mechanistically, cytoplasmic ZCCHC9 activates the JNK pathway, promoting the expression of cell cycle and invasion markers like Cyclin D1 and MMP7. Functional studies have identified that inhibition of JNK with SP600125 reverses these oncogenic effects, suggesting a direct link between ZCCHC9, the JNK pathway, and tumor progression. Its context-dependent localization and functional switch make ZCCHC9 both a potential therapeutic target and biomarker in cancers, particularly NSCLC[2][4]. Additional information: - ZCCHC9 contains multiple CCHC zinc knuckle motifs, which are characteristic of nucleic acid-binding proteins and suggest high-affinity binding for single-stranded RNA or DNA[4]. - While most of its research focus is in cancer, especially lung cancer, the protein is part of a family that broadly participates in post-transcriptional and transcriptional regulation, often through mRNA or protein-protein interactions[3][4]. No commonly used small-molecule or biologic drugs currently target ZCCHC9 in the clinic; SP600125 is a research tool compound supporting mechanistic links, not a therapy[2].

Other names

Zinc finger CCHC-type containing 9PPP1R41Protein phosphatase 1, regulatory subunit 41DKFZp761J139ZCHC9_HUMAN

Inhibition of JNK pathway (as shown by effects of SP600125 on ZCCHC9-overexpressing cells)